Michael J Gubbins

Summary

Affiliation: Public Health Agency of Canada
Country: Canada

Publications

  1. ncbi Production and characterization of a monoclonal antibody to Francisella tularensis lipopolysaccharide
    Michael J Gubbins
    Division of Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Hybridoma (Larchmt) 26:98-103. 2007
  2. ncbi Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine
    Michael J Gubbins
    Division of Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    J Immunoassay Immunochem 28:213-25. 2007
  3. ncbi Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen
    Michael J Gubbins
    Division of Vaccine Preventable Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    FEMS Immunol Med Microbiol 47:436-43. 2006
  4. ncbi Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus
    Michael J Gubbins
    National Microbiology Laboratory, Health Canada, 1015 Arlington Street, Winnipeg, Man, Canada R3E 3R2
    Mol Immunol 42:125-36. 2005
  5. ncbi A simple and rapid protocol for the sequence determination of functional kappa light chain cDNAs from aberrant-chain-positive murine hybridomas
    Xin Yuan
    The Monoclonal Antibody Section, National Microbiology Laboratory-Health Canada and the National Centre for Foreign Animal Disease-CFIA, 1015 Arlington Street, Winnipeg, Manitoba, Canada
    J Immunol Methods 294:199-207. 2004
  6. ncbi Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
    Jody D Berry
    National Centre for Foreign Animal Disease, CFIA, Winnipeg, Canada
    J Virol Methods 120:87-96. 2004

Collaborators

Detail Information

Publications6

  1. ncbi Production and characterization of a monoclonal antibody to Francisella tularensis lipopolysaccharide
    Michael J Gubbins
    Division of Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, Manitoba, Canada
    Hybridoma (Larchmt) 26:98-103. 2007
    ..Both assays showed that MAb F94G2-1 has excellent specificity for F. tularensis LPS and demonstrate the utility of using the same MAb in a variety of immunodiagnostic applications...
  2. ncbi Development of a competitive enzyme linked immunosorbent assay to identify epitope specific antibodies in recipients of the U.S. licensed anthrax vaccine
    Michael J Gubbins
    Division of Vaccine Preventable Bacterial Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    J Immunoassay Immunochem 28:213-25. 2007
    ..This assay may be used for serological confirmation of successful immunization against anthrax and for the identification of antibodies in human vaccinee serum that recognize protective epitopes on PA...
  3. ncbi Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen
    Michael J Gubbins
    Division of Vaccine Preventable Diseases, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada
    FEMS Immunol Med Microbiol 47:436-43. 2006
    ..Neutralization assays demonstrate that these mAbs effectively neutralize lethal toxin in vitro...
  4. ncbi Molecular characterization of a panel of murine monoclonal antibodies specific for the SARS-coronavirus
    Michael J Gubbins
    National Microbiology Laboratory, Health Canada, 1015 Arlington Street, Winnipeg, Man, Canada R3E 3R2
    Mol Immunol 42:125-36. 2005
    ..The results suggest that optimization of murine mAbs for neutralization of SARS-CoV infection will likely be possible, and will aid in the development of diagnostic tools and passive treatments for SARS-CoV infection...
  5. ncbi A simple and rapid protocol for the sequence determination of functional kappa light chain cDNAs from aberrant-chain-positive murine hybridomas
    Xin Yuan
    The Monoclonal Antibody Section, National Microbiology Laboratory-Health Canada and the National Centre for Foreign Animal Disease-CFIA, 1015 Arlington Street, Winnipeg, Manitoba, Canada
    J Immunol Methods 294:199-207. 2004
    ..This protocol is a rapid and convenient method for determining the sequence of murine V kappa region genes from hybridomas expressing aberrant kappa chain mRNAs...
  6. ncbi Development and characterisation of neutralising monoclonal antibody to the SARS-coronavirus
    Jody D Berry
    National Centre for Foreign Animal Disease, CFIA, Winnipeg, Canada
    J Virol Methods 120:87-96. 2004
    ..These studies highlight the importance of using standardised assays and reagents. These mAbs will be useful for the development of diagnostic tests, studies of SARS-CoV pathogenesis and vaccine development...